文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Etranacogene Dezaparvovec基因治疗血友病B

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
PubMed 文献 · N Engl J Med · 2023-01-01

这项开放标签3期研究对54名中重度血友病B男性患者单次输注etranacogene dezaparvovec(2×10¹³基因组拷贝/千克体重),比较治疗后7至18个月与导入期凝血因子IX预防治疗的年化出血率。结果显示年化出血率从导入期4.19降至治疗后1.51,率比0.36(95% Wald CI 0.20至0.64;P<0.001),证明非劣效且优效;因子IX活性较基线升高,浓缩物用量减少,未发生治疗相关严重不良事件。

要点

  • 年化出血率从导入期4.19降至治疗后7至18个月1.51,率比0.36(95% Wald CI 0.20至0.64;P<0.001)。
  • 治疗后6个月因子IX活性较基线最小二乘均值升高36.2个百分点(95% CI 31.4至41.0)。
  • 未发生治疗相关严重不良事件。

核心结论

  • Etranacogene dezaparvovec基因治疗在年化出血率方面优于凝血因子IX预防治疗,且安全性良好。

研究设计与样本

  • 开放标签3期研究,纳入54名凝血因子IX活性≤正常值2%的男性血友病B患者,无论是否存在AAV5中和抗体。
  • 经过≥6个月的凝血因子IX预防治疗导入期后,单次输注表达Padua因子IX变体的AAV5载体etranacogene dezaparvovec(2×10¹³基因组拷贝/千克体重)。
  • 主要终点为年化出血率,采用非劣效性分析比较治疗后7至18个月与导入期的年化出血率。
  • 非劣效性定义为年化出血率比值的双侧95% Wald置信区间上限小于非劣效界值1.8。

主要发现

  • 年化出血率从导入期4.19(95% CI 3.22至5.45)降至治疗后7至18个月1.51(95% CI 0.81至2.82),率比0.36(95% Wald CI 0.20至0.64;P<0.001),证明非劣效且优效。
  • 治疗后6个月因子IX活性较基线最小二乘均值升高36.2个百分点(95% CI 31.4至41.0),18个月升高34.3个百分点(95% CI 29.5至39.1)。
  • 治疗后期间凝血因子IX浓缩物使用量平均每年每参与者减少248,825 IU(P<0.001)。
  • 在预给药AAV5中和抗体滴度低于700的参与者中观察到获益和安全性。
  • 未发生治疗相关严重不良事件。

关键数值与推荐

  • 非劣效性界值为年化出血率比值的双侧95% Wald置信区间上限小于1.8。
  • 主要终点年化出血率率比0.36(95% Wald CI 0.20至0.64;P<0.001)。
  • 因子IX活性较基线最小二乘均值升高:6个月36.2个百分点(95% CI 31.4至41.0),18个月34.3个百分点(95% CI 29.5至39.1)。
  • 凝血因子IX浓缩物使用量平均每年每参与者减少248,825 IU(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Moderate-to-severe hemophilia B is treated with lifelong, continuous coagulation factor IX replacement to prevent bleeding. Gene therapy for hemophilia B aims to establish sustained factor IX activity, thereby protecting against bleeding without burdensome factor IX replacement. METHODS: In this open-label, phase 3 study, after a lead-in period (≥6 months) of factor IX prophylaxis, we administered one infusion of adeno-associated virus 5 (AAV5) vector expressing the Padua factor IX variant (etranacogene dezaparvovec; 2×1013 genome copies per kilogram of body weight) to 54 men with hemophilia B (factor IX activity ≤2% of the normal value) regardless of preexisting AAV5 neutralizing antibodies. The primary end point was the annualized bleeding rate, evaluated in a noninferiority analysis comparing the rate during months 7 through 18 after etranacogene dezaparvovec treatment with the rate during the lead-in period. Noninferiority of etranacogene dezaparvovec was defined as an upper limit of the two-sided 95% Wald confidence interval of the annualized bleeding rate ratio that was less than the noninferiority margin of 1.8. Superiority, additional efficacy measures, and safety were also assessed. RESULTS: The annualized bleeding rate decreased from 4.19 (95% confidence interval [CI], 3.22 to 5.45) during the lead-in period to 1.51 (95% CI, 0.81 to 2.82) during months 7 through 18 after treatment, for a rate ratio of 0.36 (95% Wald CI, 0.20 to 0.64; P<0.001), demonstrating noninferiority and superiority of etranacogene dezaparvovec as compared with factor IX prophylaxis. Factor IX activity had increased from baseline by a least-squares mean of 36.2 percentage points (95% CI, 31.4 to 41.0) at 6 months and 34.3 percentage points (95% CI, 29.5 to 39.1) at 18 months after treatment, and usage of factor IX concentrate decreased by a mean of 248,825 IU per year per participant in the post-treatment period (P<0.001 for all three comparisons). Benefits and safety were observed in participants with predose AAV5 neutralizing antibody titers of less than 700. No treatment-related serious adverse events occurred. CONCLUSIONS: Etranacogene dezaparvovec gene therapy was superior to prophylactic factor IX with respect to the annualized bleeding rate, and it had a favorable safety profile. (Funded by uniQure and CSL Behring; HOPE-B ClinicalTrials.gov number, NCT03569891.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Pipe SW, Leebeek FWG, Recht M, et al. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. N Engl J Med. 2023. PMID: 36812434. doi:10.1056/NEJMoa2211644

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。